Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy

Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to support an increase in the number of trial participants. Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. ("Filament"), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide. The Company is pleased to announce that Filament has expanded its supply and licence agreement with the University G. d'Annunzio of Chieti-Pescara (the "University") for the supply of PEX010 to TEMPO, a clinical trial of psilocybin for treatment-resistant depression conducted at the Psychiatric Clinic of the University in Chieti, Italy. TEMPO was authorized under the European Union Clinical Trials Regulation (EU CT number 2025-523346-27-00). During the regulatory review, the number of trial participants was increased, and the amended agreement expands the supply of PEX010 25 mg capsules to match. Filament also provides regulatory support for the trial and release of PEX010 for use in the European Union. The trial is coordinated with the Istituto Superiore di Sanità (the Italian National Institute of Health) and has been reported in the Italian press as the first clinical trial of psilocybin in Italy. The University is the sponsor of the trial. Filament is not the sponsor of the trial and is not responsible for its conduct. PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. PEX010 is available in a standardized dosing range of 1, 5 and 25 mg from a single drug candidate, with a 0.5 mg dose to follow, produced using Filament's proprietary and patented extraction, purification and stabilization methods, giving investigators consistent composition across every dose, every study and every research site. On April 30, 2026, the Company completed its previously announced acquisition of Filament Health Corp., including its lead drug candidate, PEX010, and its portfolio of 78 issued patents across 13 patent families. About Rhelion Life Sciences: Rhelion Life Sciences is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.